The Shingle Solution™ By Julissa Clay This eBook includes a program to treat the problem of shingle naturally. The author of this eBook, Julissa Clay, a practitioner in natural health, has killed the shingles causing virus completely to overcome the problem of PHN or Postherpetic neuralgia, one of the common complications caused by shingles. This program helps in melting PHN in a few weeks and make shingles a forgotten nightmare.
How does shingles prevalence differ worldwide in elderly populations, what percentage of people over 65 are affected, and how do regional vaccination programs compare?
🌍 A Tale of Two Worlds: Shingles in the Elderly Across the Globe 👵
Shingles, or herpes zoster, stands as a near-universal threat to the aging population, a painful reactivation of the dormant chickenpox virus that strikes as the immune system wanes. While the biological mechanism is consistent, the real-world impactfrom the likelihood of an elderly person developing the debilitating rash to their ability to access a preventive vaccinediffers dramatically across the globe. This disparity in prevalence, risk, and prevention creates a tale of two distinct worlds: one where shingles is a recognized and increasingly preventable public health issue, and another where it remains a common, unaddressed affliction of aging. The worldwide prevalence of shingles in elderly populations is universally high but varies based on regional demographics and data collection, affecting a substantial percentage of all people over 65, with regional vaccination programs representing the starkest point of comparison, ranging from comprehensive national initiatives to near non-existence.
📈 The Global Footprint of Shingles in the Elderly
The fundamental risk factor for shingles is a previous infection with the varicella-zoster virus (VZV), which causes chickenpox. As VZV is endemic worldwide, nearly every adult is a potential candidate for shingles. The incidence of the disease begins to climb steeply around the age of 50, a phenomenon attributed to immunosenescence, the natural, age-related decline in immune function. Globally, the overall incidence rate of shingles in the general population is estimated to be between 3 and 5 cases per 1,000 person-years. However, for adults over the age of 65, this rate often doubles to over 10 cases per 1,000 person-years. This means that in a group of one thousand 70-year-olds, one could expect about ten new cases of shingles to occur each year.
While data varies, the trends are consistent across high-income countries in North America, Europe, and the Asia-Pacific region. Studies in the United States, for example, consistently show incidence rates in the elderly that exceed 11 per 1,000 person-years. Similarly, European countries report rates ranging from 7 to 11 per 1,000 for those over 60. Data from Asian countries like South Korea, Taiwan, and Japan show a comparable, and in some cases even higher, burden, with rates for those over 65 often surpassing 10 per 1,000 person-years. This consistency underscores that, in the absence of vaccination, shingles is an inevitable consequence of aging for a significant portion of the population, regardless of geography in the developed world.
However, a significant data gap exists for many low- and middle-income regions, particularly in Africa and South America. In these areas, herpes zoster is often under-diagnosed and under-reported. The limited studies available frequently focus on immunocompromised populations, such as those with HIV, where shingles rates are exceptionally high. While age remains the primary risk factor, the true incidence in the general elderly population in these regions is not well-documented, though it is presumed to be substantial.
Regarding the overall percentage of elderly individuals affected, the statistics are striking. It is widely cited that approximately one in three people will develop shingles in their lifetime. As the risk is heavily weighted towards older age, this burden falls disproportionately on seniors. For those who live to the age of 85, the lifetime risk increases to as high as 50%, meaning one of every two people reaching this age will have experienced at least one episode of shingles. This illustrates the immense scale of the problem and the vast number of elderly individuals worldwide who suffer from the acute pain of the rash and the potential for debilitating long-term complications like postherpetic neuralgia (PHN).
💉 A World Divided: The Vaccination Landscape
The most dramatic difference in the global shingles story is the approach to prevention through vaccination. Here, the world is clearly divided into regions with established, publicly funded vaccination programs and those without.
North America and parts of Europe and the Asia-Pacific lead the way with robust national immunization programs. The United States provides a strong example, where the Advisory Committee on Immunization Practices (ACIP) recommends the recombinant zoster vaccine (RZV), Shingrix, for all immunocompetent adults aged 50 and older. With an efficacy of over 90% in preventing shingles across all age groups, Shingrix has become the gold standard. It replaced the older, live-attenuated vaccine (Zostavax), which had significantly lower efficacy, especially in the oldest age groups. The vaccine is widely available and typically covered by insurance plans.
The United Kingdom also has a national shingles immunization program, but its strategy has been more targeted, historically offering the vaccine to people within specific age cohorts, such as those turning 65 or 70. The UK has also made the decisive shift from Zostavax to the more effective Shingrix, recognizing its superior and longer-lasting protection. Similarly, Australia launched a national shingles vaccination program in 2016 and now provides Shingrix free of charge to people aged 65 and over, acknowledging the significant public health burden of the disease in its aging population. Other countries like Germany and Canada have also implemented similar publicly funded programs recommending Shingrix for their older citizens.
In stark contrast, the situation in most of Asia, Africa, and South America is vastly different. In these regions, national immunization programs for shingles are virtually non-existent. While the highly effective Shingrix vaccine may be approved for use, it is typically only available through the private market. This creates a significant barrier to access due to cost. In many countries, the price of the two-dose Shingrix vaccine can be prohibitively expensive, equivalent to a substantial portion of an average person’s monthly income. For instance, in countries like Thailand or Brazil, the vaccine is available, but patients must pay out-of-pocket, limiting its use to those with the financial means.
The situation is even more dire in much of Africa. In many African nations, the shingles vaccine is not a public health priority amidst more pressing infectious disease challenges. As highlighted in South Africa, even when a demand exists, the newer, more effective Shingrix vaccine may not even be registered for use, let alone included in a public program. This leaves the vast majority of the elderly population with no viable option for prevention, forced to endure a painful condition that is largely preventable in wealthier parts of the world. This disparity means that for an elderly person in the US or UK, shingles is increasingly becoming an optional disease, whereas for their counterpart in much of the developing world, it remains an almost inevitable rite of passage of old age. This vaccination gap is perhaps the most critical factor differentiating the global experience of shingles in the elderly today.
The Shingle Solution™ if you are suffering from shingles then The Shingle Solution can be the best program for you to relieve your pain and itching by using a natural remedy. It describes the ways to use this program so that you can feel the difference after using it as directed. This natural remedy for shingles can also help in boosting your immune system along with repairing your damaged nerves and relieve pain and itching caused by shingles
I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more |